Search

Your search keyword '"Hebart, Holger"' showing total 14 results
Start Over Author "Hebart, Holger" Publisher wiley
14 results on '"Hebart, Holger"'

1. Preinfection laboratory parameters may predict COVID‐19 severity in tumor patients

Author

Kiani, Alexander, primary, Roesch, Romina, additional, Wendtner, Clemens M., additional, Kullmann, Frank, additional, Kubin, Thomas, additional, Südhoff, Thomas, additional, Augustin, Marinela, additional, Schaich, Markus, additional, Müller‐Naendrup, Clemens, additional, Illerhaus, Gerald, additional, Hartmann, Frank, additional, Hebart, Holger, additional, Seggewiss‐Bernhardt, Ruth, additional, Bentz, Martin, additional, Späth‐Schwalbe, Ernst, additional, Reimer, Peter, additional, Kaiser, Ulrich, additional, Kapp, Markus, additional, Graeven, Ullrich, additional, Chemnitz, Jens‐Marcus, additional, Baesecke, Jörg, additional, Lambertz, Helmut, additional, and Naumann, Ralph, additional

Published
2021
Full Text
View/download PDF

2. Nintedanib plusmFOLFOX6as second‐line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo‐controlled, phaseII TRICC‐Cstudy (AIO‐KRK‐0111)

Author

Ettrich, Thomas J., primary, Perkhofer, Lukas, additional, Decker, Thomas, additional, Hofheinz, Ralf‐Dieter, additional, Heinemann, Volker, additional, Hoffmann, Thomas, additional, Hebart, Holger F., additional, Herrmann, Thomas, additional, Hannig, Carla V., additional, Büchner‐Steudel, Petra, additional, Güthle, Melanie, additional, Hermann, Patrick C., additional, Berger, Andreas W., additional, and Seufferlein, Thomas, additional

Published
2020
Full Text
View/download PDF

3. Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC)

Author

Lorenzen, Sylvie, primary, Knorrenschild, Jorge Riera, additional, Pauligk, Claudia, additional, Hegewisch‐Becker, Susanna, additional, Seraphin, Jörg, additional, Thuss‐Patience, Peter, additional, Kopp, Hans‐Georg, additional, Dechow, Tobias, additional, Vogel, Arndt, additional, Luley, Kim Barbara, additional, Pink, Daniel, additional, Stahl, Michael, additional, Kullmann, Frank, additional, Hebart, Holger, additional, Siveke, Jens, additional, Egger, Matthias, additional, Homann, Nils, additional, Probst, Stephan, additional, Goetze, Thorsten Oliver, additional, and Al‐Batran, Salah‐Eddin, additional

Published
2020
Full Text
View/download PDF

4. HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

Author

Stevens, Wendy B.C., primary, Bakunina, Katerina, additional, Cuijpers, Marloes, additional, Chamuleau, Martine, additional, Beeker, Aart, additional, Fijnheer, Rob, additional, Hebart, Holger, additional, Visser, Hein P.J., additional, Doorduijn, Jeanette K., additional, Linton, Kim, additional, Dreyling, Martin, additional, de Jong, Daphne, additional, and Kersten, Marie José, additional

Published
2020
Full Text
View/download PDF

5. Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen ( RADPAC )

Author

Lorenzen, Sylvie, Knorrenschild, Jorge Riera, Pauligk, Claudia, Hegewisch‐Becker, Susanna, Seraphin, Jörg, Thuss‐Patience, Peter, Kopp, Hans‐Georg, Dechow, Tobias, Vogel, Arndt, Luley, Kim Barbara, Pink, Daniel, Stahl, Michael, Kullmann, Frank, Hebart, Holger, Siveke, Jens, Egger, Matthias, Homann, Nils, Probst, Stephan, Goetze, Thorsten Oliver, and Al‐Batran, Salah‐Eddin

Subjects
ddc
Published
2019

7. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia

Author

Robak, Tadeusz, Hellmann, Andrzej, Kloczko, Janusz, Loscertales, Javier, Lech-Maranda, Ewa, Pagel, John M., Mato, Anthony, Byrd, John C., Awan, Farrukh T., Hebart, Holger, Garcia-Marco, Jose A., Hill, Brian T., Hallek, Michael, Eisenfeld, Amy J., Stromatt, Scott C., Jaeger, Ulrich, Robak, Tadeusz, Hellmann, Andrzej, Kloczko, Janusz, Loscertales, Javier, Lech-Maranda, Ewa, Pagel, John M., Mato, Anthony, Byrd, John C., Awan, Farrukh T., Hebart, Holger, Garcia-Marco, Jose A., Hill, Brian T., Hallek, Michael, Eisenfeld, Amy J., Stromatt, Scott C., and Jaeger, Ulrich

Abstract

Otlertuzumab (TRU-016) is a humanized anti-CD37 protein therapeutic that triggers direct caspase-independent apoptosis of malignant B cells and induces antibody-dependent cell-mediated cytotoxicity. Patients with relapsed chronic lymphocytic leukaemia (CLL) received either otlertuzumab (20mg/kg) weekly by IV infusion for two 28-day cycles then every 14days for four 28-day cycles and IV bendamustine (70mg/m(2)) on Days 1 and 2 of each cycle for up to six 28-day cycles or bendamustine alone. Thirty-two patients were treated with otlertuzumab and bendamustine and 33 with bendamustine alone. Overall response rate according to the International Workshop on Chronic Lymphocytic Leukaemia criteria was 69% in the otlertuzumab and bendamustine arm and 39% in the bendamustine alone arm (P=0025). Median progression-free survival (PFS) was 159months in the otlertuzumab and bendamustine arm and 102months in the bendamustine alone arm (P=00192). There was a higher incidence of pyrexia (34% vs. 12%) and neutropenia (59% vs. 39%) with the combination but this did not result in a higher incidence of severe (grade 3/4) infections (13% vs. 27%). This combination significantly increased the response rate and prolonged the PFS over single agent bendamustine in patients with relapsed or refractory CLL.

Published
2017

8. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial

Author

Einsele, Hermann, primary, Engelhardt, Monika, additional, Tapprich, Christoph, additional, Müller, Jürgen, additional, Liebisch, Peter, additional, Langer, Christian, additional, Kropff, Martin, additional, Mügge, Lars O., additional, Jung, Wolfram, additional, Wolf, Hans-Heinrich, additional, Metzner, Bernd, additional, Hart, Christina, additional, Gramatzki, Martin, additional, Hertenstein, Bernd, additional, Pfreundschuh, Michael, additional, Rösler, Wolf, additional, Fischer, Thomas, additional, Maschmeyer, Georg, additional, Kanz, Lothar, additional, Hess, Georg, additional, Jäger, Elke, additional, Bentz, Martin, additional, Dürk, Heinz A., additional, Salwender, Hans, additional, Hebart, Holger, additional, Straka, Christian, additional, and Knop, Stefan, additional

Published
2017
Full Text
View/download PDF

9. Randomized phase 2 study of otlertuzumab and bendamustineversusbendamustine in patients with relapsed chronic lymphocytic leukaemia

Author

Robak, Tadeusz, primary, Hellmann, Andrzej, additional, Kloczko, Janusz, additional, Loscertales, Javier, additional, Lech-Maranda, Ewa, additional, Pagel, John M., additional, Mato, Anthony, additional, Byrd, John C., additional, Awan, Farrukh T., additional, Hebart, Holger, additional, Garcia-Marco, Jose A., additional, Hill, Brian T., additional, Hallek, Michael, additional, Eisenfeld, Amy J., additional, Stromatt, Scott C., additional, and Jaeger, Ulrich, additional

Published
2016
Full Text
View/download PDF

13. Ex vivogeneration of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells

Author

Kleihauer, Annette, primary, Grigoleit, Ulrich, additional, Hebart, Holger, additional, Moris, Arnaud, additional, Brossart, Peter, additional, Muhm, Alexandra, additional, Stevanovic, Stefan, additional, Rammensee, Hans Georg, additional, Sinzger, Christian, additional, Riegler, Susanne, additional, Jahn, Gerhard, additional, Kanz, Lothar, additional, and Einsele, Hermann, additional

Published
2001
Full Text
View/download PDF

14. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia

Author

Hebart, Holger, primary, Loffler, Jurgen, additional, Reitze, Heike, additional, Engel, andreas, additional, Schumacher, Ulrike, additional, Klingebiel, Thomas, additional, Bader, Peter, additional, Bohme, Angelika, additional, Martin, Hans, additional, Bunjes, Donald, additional, Kern, Winfried V., additional, Kanz, Lothar, additional, and Einsele, Hermann, additional

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results